The Push for American-Made Peptides
A movement to bring peptide production back to the US gains momentum
1Peptide Party on a WWII Ship
A black-tie peptide party was hosted on the SS Jeremiah O’Brien, a WWII Liberty ship, by Gen Z venture capitalists from Haus Fund. The event showcased four peptide samples, including GHK-Cu cream and sublingual strips from startup Afterglow. The venue symbolized American industrial prowess and the push to bring pharmaceutical production back to the US.
2Gray Market Concerns
The US pharmaceutical supply chain relies heavily on imports, with 51% of active pharmaceutical ingredients coming from India and the EU, and 10% from China. Gray-market peptides, often sourced from China, raise concerns about safety and accountability. The US Department of Health and Human Services recently allowed unapproved peptides for compounding, sparking debate.
3FDA’s Stance on Peptides
FDA scientists have expressed concerns about the safety and efficacy of unapproved peptides, stating there’s insufficient evidence. The HHS decision to allow compounding bypasses traditional clinical trials, potentially creating a parallel, less-regulated market. Industry experts warn this could undermine the clinical trial framework.
4Haus Fund’s Vision
Haus Fund’s Roxana Grunenwald, Yuva Krishnapillai, and Elia Ahmadi advocate for American-made peptides, emphasizing safety and regulatory oversight. They argue that domestic production would ensure accountability and align with US consumer safety laws. Their event aimed to highlight the importance of rebuilding pharmaceutical manufacturing in the US.
5Challenges of Onshoring
Returning pharmaceutical production to the US faces significant hurdles, including cost and infrastructure. Decades of globalization have shifted the US to a services-based economy. Building a domestic peptide supply chain would require substantial investment and time, but proponents believe it’s essential for long-term safety and quality.
6Hims & Hers’ Initiative
Hims & Hers, a leading telehealth brand, is investing in US peptide manufacturing. They acquired a facility in California and plan to launch Peptides Plus, offering compounds like Sermorelin and Glutathione. The company aims to ensure quality and regulatory consistency by overseeing the entire production process domestically.
7Regulatory Inconsistencies
Elia Ahmadi highlights the inconsistency in compounding pharmacy practices, which vary based on individual recommendations. Domestic production would allow the US to enforce uniform regulations and set global standards for peptide quality and safety. This move is seen as a step toward greater accountability in the pharmaceutical industry.
8Consumer Concerns
Gray-market peptide users often face anxiety over importing unregulated substances. While American-made peptides may be more expensive, proponents argue the cost is justified by higher safety standards. The shift could provide consumers with reliable, domestically produced alternatives to unverified imports.
9Future of Peptide Production
The HHS decision is an interim policy, and its long-term impact remains uncertain. The push for American-made peptides reflects broader concerns about reliance on foreign manufacturing. While challenges persist, advocates believe domestic production is crucial for ensuring safety, quality, and regulatory oversight in the growing peptide market.
Original article: The Verge — The Push for American-Made Peptides